L

Lyell Immunopharma

271 employees

Lyell Immunopharma is an operator of a biotechnology company that develops cellular therapies to cure cancer.

Investor insights

Sectors invested in

Biotechnology5
Therapeutics4
Life Science3
Health Care2
CART1
Pharmaceutical1
Medical1
Solid Tumors1
Immunology1
Adoptive Cell Therapy1
Cellular Immunotherapy1
Molecular Immunology1
Gene Engineering1
Hematopoietic Cell Transplantation1
Flow Cytometry1
Tumor Immunology1
Immuno Oncology1
Molecular Biology1
Synthetic Biology1
Phage Display1

Funding rounds participated in

$40M sweet spot round size

Most of their 6 investments are in rounds between $30M and $45M

Basic info

Industry

biotechnology research

Sectors

Biotechnology
Health Care
Medical
Pharmaceutical

Date founded

2018

Investments made

O

Outpace Bio raised $30M on March 31, 2021

Investors: ARTIS Ventures, Washington Research Foundation, Abstract Ventures, Civilization Ventures, Playground Global, Sahsen Ventures, LLC and Lyell Immunopharma

U

Undisclosed raised $70M on September 30, 2020

Investors: Lilly Asia Ventures, Octagon Capital, Lifeforce Capital, 8VC, JDRF T1D Fund, ARCH Venture Partners and Lyell Immunopharma

S

Sonoma Biotherapeutics raised $30M on September 30, 2020

Investors: Octagon Capital, Lilly Asia Ventures, JDRF T1D Fund, Lifeforce Capital, 8VC, ARCH Venture Partners and Lyell Immunopharma

C

CERo Therapeutics, Inc. raised $40M on March 18, 2020

Investors: Sequoia Capital China, ARCH Venture Partners and Lyell Immunopharma

E

Eureka Therapeutics, Inc raised $45M on March 17, 2020

Investors: Lyell Immunopharma

S

Sonoma Biotherapeutics raised $40M on February 6, 2020

Investors: 8VC, Milky Way Ventures, ARCH Venture Partners and Lyell Immunopharma

FAQ